Prosecution Insights
Last updated: April 19, 2026
Application No. 18/038,349

PEPTIDE COMPOUND PRODUCTION METHOD

Non-Final OA §103§112
Filed
May 23, 2023
Examiner
SABILA, MERCY HELLEN
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Chubu University Educational Foundation
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
2y 8m
To Grant
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allow Rate
152 granted / 257 resolved
-0.9% vs TC avg
Strong +46% interview lift
Without
With
+45.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
56 currently pending
Career history
313
Total Applications
across all art units

Statute-Specific Performance

§101
3.2%
-36.8% vs TC avg
§103
42.0%
+2.0% vs TC avg
§102
15.9%
-24.1% vs TC avg
§112
20.8%
-19.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 257 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application was filed on and is a U.S. national Stage application under 35 U.S.C. 371 of International Patent Application No. PCT/JP2022/024418 filed 06/17/2022, which claims the benefit of the priority of Japan Patent Application No. 2021-101016 filed 06/17/2021. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statements submitted on 08/17/2023 and 07/02/2025 have been considered by the examiner. Claim Status Claims 1-6 are being examined on the merits in this office action. Claim Objections Claims 5-6 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim. See MPEP § 608.01(n). Accordingly, the claims have not been further treated on the merits. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-4 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the claim contain a parenthesis in line 8 and 15. It is unclear whether the limitations in the parenthesis are a required part of the claimed invention. Claims 2-4 depend on claim 1 and are similarly rejected. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-4 are rejected under 35 U.S.C. 103 as being unpatentable over Yamamoto et al. (WO2019208731A1 – hereinafter “Yamamoto”). Yamamoto teaches a production method comprising reacting the compound 1 PNG media_image1.png 157 450 media_image1.png Greyscale with the compound 2 PNG media_image2.png 151 471 media_image2.png Greyscale to produce the compound PNG media_image3.png 152 680 media_image3.png Greyscale (Page 1-2). Yamamoto teaches R1, R2, R4, and R5 each independently represent a hydrogen atom, halogen atom, hydroxy group, carboxyl group, nitro group, cyano group, or thiol group, or monovalent hydrocarbon group or heterocyclic group, which may have one, two, or more substituents, A1 to A4 each independently represent a divalent aliphatic hydrocarbon group having 1 to 3 carbon atoms, which may have one, two, or more substituents (Page 2), p1 to p4 each independently represent 0 or 1 (Page 2), m and n are each independently an integer of 1 or higher (Page 2), PG2 represents a protecting group of the carboxyl group, PG1 represents a protecting group of the amino group (Page 2). Examiner notes that the circled group on the product compound above is a bivalent group and represents instant L1, wherein q1 is 0. Yamamoto does not explicitly teach that compound 1 is a lactam ring, however, Yamamoto teaches that R 1 and R 3 are bonded to each other to form a heterocyclic ring which may have one or more substituents together with the carbon atom to which R 1 is bonded and the nitrogen atom to which R 3 is bonded (Page 2) and that the Lewis acid catalyst is suitable for the compound being a seven-membered ring compound (Page 17, 7th paragraph). Examiner notes that the teachings of Yamamoto read on the instant Formula 1-3, and read on Formula 1 being a lactam ring. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the method taught by Yamamoto and make the compound 1 a lactam ring since Yamamoto teaches that the Lewis acid catalyst used in the method is suitable for the compound being a seven-membered ring compound (Page 17, 7th paragraph). Thus, one of ordinary skill in the art would be motivated and would have had a reasonable expectation of success in using modifying compound 1 to a ring compound for efficient production of the polypeptide. The disclosure renders obvious claim 1. Regarding claim 2, Yamamoto teaches that specific examples of the amino protecting group PG1 include tert-butoxycarbonyl group (Boc), benzyloxycarbonyl group (Cbz), benzoyl group (Bz), 2,2,2-trichloroethoxycarbonyl group (Troc), allyloxycarbonyl group (Alloc), phthaloyl group (Phth), paramethoxybenzoyl group (PMPCO), cinnamoyl group, toluenesulfonyl group (Ts), 2 or 4-nitrobenzenesulfonyl group (Ns), cyanomethyl group, 9-fluorenylmethyloxycarbonyl group (Fmoc) (Page 15, 1st paragraph). Regarding claim 3, Yamamoto teaches A1 represent a divalent aliphatic hydrocarbon group having 1 to 3 carbon atoms, which may have one, two, or more substituents (Page 2), p1 to p4 each independently represent 0 or 1 (Page 2). Examiner notes that the circled group on the product compound above is a bivalent group and represents instant L1, wherein q1 is 0. Regarding claim 4, Yamamoto teaches the compound PNG media_image3.png 152 680 media_image3.png Greyscale (Page 1-2). wherein R1, R2, R4, and R5 each independently represent a hydrogen atom, halogen atom, hydroxy group, carboxyl group, nitro group, cyano group, or thiol group, or monovalent hydrocarbon group or heterocyclic group, which may have one, two, or more substituents. Yamamoto teaches A1 represent a divalent aliphatic hydrocarbon group having 1 to 3 carbon atoms, which may have one, two, or more substituents (Page 2), p1 to p4 each independently represent 0 or 1 (Page 2). Examiner notes that the disclosure reads on L1 is —C(═O)—N—. Further, Yamamoto teaches linking groups such as PNG media_image4.png 220 140 media_image4.png Greyscale (Page 13, last paragraph) which reads on —C(═O)—N—. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mercy H. Sabila whose telephone number is (571)272-2562. The examiner can normally be reached Monday - Friday 5:00 am - 3:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko G. Garyu can be reached at (571)270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MERCY H SABILA/Examiner, Art Unit 1654
Read full office action

Prosecution Timeline

May 23, 2023
Application Filed
Feb 24, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595286
FUCOSE-BINDING PROTEIN, METHOD FOR PRODUCING SAME, AND USE OF SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12577282
GALECTIN-1/ GALECTIN-3 CHIMERAS AND MULTIVALENT PROTEINS
2y 5m to grant Granted Mar 17, 2026
Patent 12565516
CARRIER PROTEIN FOR IMPROVING PROPERTIES OF BIOACTIVE PROTEIN
2y 5m to grant Granted Mar 03, 2026
Patent 12534514
BIOLOGICAL AND SYNTHETIC MOLECULES INHIBITING RESPIRATORY SYNCYTIAL VIRUS INFECTION
2y 5m to grant Granted Jan 27, 2026
Patent 12528839
CONJUGATED VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTI-TUMOR IMMUNE REDIRECTORS
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+45.7%)
2y 8m
Median Time to Grant
Low
PTA Risk
Based on 257 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month